<DOC>
	<DOCNO>NCT02344940</DOCNO>
	<brief_summary>To compare safety toremifene tamoxifen therapy premenopausal patient operable breast cancer monitor gynecological abnormality , blood lipid level , hepatic abnormality , estrogen level perimenopausal symptom .</brief_summary>
	<brief_title>Safety Toremifene Tamoxifen Therapy Premenopausal Patients With Operable Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Toremifene</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>1 . Women age ≥18 year , premenopausal 2 . Histologically confirm invasive breast cancer core needle biopsy , hormonal receptor positive , define estrogen receptor ( ER ) /progesterone receptor ( PR ) positive 3 . Patients must receive standard local therapy : normalize modify radical mastectomy breast conserve surgery negative margin postsurgical radiotherapy . Patient complete adjuvant therapy accord condition , include adjuvant radiotherapy , neoadjuvant adjuvant chemotherapy . 4 . Leukocyte ≥ 3*109/L ; Platelets ≥ 75*109/L ; Serum glutamate oxaloacetate ( AST/SGOT ) serum glutamicpyruvic transaminase ( ALT/SGPT ) &lt; 2.5 time upper limit normal ( UNL ) range Serum creatinine/blood urea nitrogen ( BUN ) ≤ upper limit normal ( UNL ) range ; Written inform consent accord local ethic committee requirement . 5 . Has Eastern Cooperative Oncology Group ( ECOG ) Performance Score 02 ; 1 . Histologically confirm hormonal receptor negative . 2 . Have receive neoadjuvant/adjuvant endocrine therapy . 3 . With metastatic tumor . 4 . Family history endometrial cancer ovarian cancer kind gynecological malignant tumor . 5 . Have already detect ovarian abnormality endometrial thicken transvaginal ultrasound . 6 . With complication increase sex hormone level : pituitary adenoma，ovarian tumor , thymic cancer，etc . 7 . With complication decrease sex hormone level : hyperthyroidism，hypothyroidism，liver cirrhosis，severe malnutrition，Turner 's syndrome，sex hormone synthetase deficiency , intracranial tumor , pituitary atrophy , etc . 8 . Ovarian ablation suppression 9 . With severe nonmalignant comorbidity influence longterm follow . 10 . With severe hepatic dysfunction , ChildPugh C. 11 . With severe cardiac dysfunction , New York Heart Association ( NYHA ) grade III worse . 12 . Known severe hypersensitivity drug study ;</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>operable</keyword>
	<keyword>premenopausal</keyword>
	<keyword>endocrine therapy</keyword>
	<keyword>safety</keyword>
	<keyword>tamoxifen</keyword>
	<keyword>toremifene</keyword>
</DOC>